Rhythm Owes LG Chem $350 Million Over Four Years, Backed By A $750 Million Loan Only $250 Million Funded
Rhythm Pharmaceuticals will pay to cut a bivamelagon royalty to 1%, while two later loan tranches depend on conditions or lender consent.
Rhythm Pharmaceuticals, a biopharmaceutical company that sells drugs for rare diseases of hunger and weight, committed on November 2 to $350 million of fixed payments to LG Chem spread across four years, according to its quarterly report filed Tuesday. The deal cuts the royalty on bivamelagon, a drug candidate licensed from LG Chem, to 1%, and comes with a new five-year loan from KKR's HealthCare Royalty and Blackstone.
A front-loaded bill
Of the $350.0 million, $70.0 million is due within 15 business days of the amendment's effective date. Then come $100.0 million in September 2027, $100.0 million in September 2028 and $80.0 million in September 2029.
The royalty falls from a low-to-mid single-digit rate to a 1% base on net sales across Rhythm's MC4R portfolio. It starts on the earlier of January 1, 2029 or bivamelagon's first commercial sale.
If LG Chem consents in writing, Rhythm may swap the cash due in 2027, 2028 and 2029 for a slightly higher royalty, in the low single digits. Milestone payments can now reach up to $405 million, including the original $205 million; the prior quarter's 10-Q carried the $205 million figure. Rhythm paid LG Chem $40.0 million in July 2025 under the original license.
A loan only partly committed
The loan facility totals up to $750.0 million, but only $250.0 million is funded at closing. Another $250.0 million is a delayed-draw commitment available through June 30, 2028, subject to borrowing conditions, in no more than three draws. The last $250.0 million is uncommitted and depends on lenders agreeing, in their sole discretion.
Borrowings carry interest at adjusted term SOFR plus 4.60%, with a 1.00% floor on SOFR, and each funding bears a 1.00% original issue discount. The loan matures November 2, 2031. Rhythm must hold at least $50.0 million of qualified cash.
Health Care Royalty's existing deal was also revised, with security now limited and the payment tiers and caps untouched.
Cash before the new money
Rhythm held $320.9 million in cash and short-term investments at September 30, according to its earnings release, a figure that excludes the $250 million initial loan draw and the $70 million first LG Chem payment. Management expects cash plus the initial loan proceeds to fund planned operations for at least 24 months.
The filing cautions that the deals add debt-service burdens and fixed and contingent commitments, and that undrawn delayed-draw money is not cash on hand for operations. Rhythm is still weighing how to account for the revised agreement.
Third-quarter product revenue was $92.1 million, against $51.3 million a year earlier, and the net loss was $41.4 million. Rhythm's market value was $6.4 billion in Tuesday's report.
The $70 million first LG Chem installment falls due within 15 business days of the amendment's effective date.
Sources
- 10-Q Filing — Rhythm Pharmaceuticals (RYTM) — SEC EDGAR
- 10-Q Filing — Rhythm Pharmaceuticals (RYTM), Q2 FY2026 filed 2026-08-04 (comparison basis) — SEC EDGAR
- Earnings release (8-K Item 2.02, q32026earningspr.htm) — Rhythm Pharmaceuticals, filed 2026-11-03 — SEC EDGAR